Forward to a Friend

  • Good news travels fast! If you would like to recommend the Helixate FS.com Web site to a friend or colleague, simply provide the person’s name and e-mail address, and we'll contact them for you. Here is a copy of the message that will be sent:

    [Your name] thought you might be interested in the Helixate FS Web site. The site contains information, resources and tools about living with and treating Hemophilia A.

    Click the link below, or copy and paste it into your browser, to find out more.

    www.helixatefs.com

  • All fields are required.

  • Type in the verification word in the box below and click "Submit."

    Verification Word

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.